文献速递造血干细胞移植与细胞治疗

Wiskott-Aldrich综合征造血细胞移植后结局优异:PIDTC报告

Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
PubMed 文献 · Blood · 2020-01-01

该研究纳入2005至2015年间29个PIDTC中心接受HCT的129例WAS患者,中位移植年龄1.2岁,65%接受白消安为基础的清髓预处理。中位随访4.5年,5年OS为91%;<5岁移植者OS优于≥5岁者(94% vs 66%)。供者类型不影响OS,但预处理强度与供者髓系嵌合及血小板恢复相关。

要点

  • WAS患者HCT后5年OS达91%,<5岁移植者OS显著优于≥5岁者。
  • 供者类型不影响OS,脐血移植者OS亦达90%。
  • 高比例供者髓系嵌合与更高血小板计数相关。

核心结论

  • WAS患者HCT后5年OS为91%,较既往报告改善。
  • 高比例供者髓系嵌合与HCT后更高血小板计数相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入2005至2015年29个PIDTC中心129例WAS患者。
  • 中位移植年龄1.2岁,65%接受白消安为基础的清髓预处理,中位随访4.5年。
  • 临床试验注册号NCT02064933。

主要发现

  • 5年OS为91%。
  • 各供者类型OS均优异,脐血移植受者OS为90%。
  • 预处理强度不影响OS,但影响供者T细胞和髓系植入。
  • 接受氟达拉滨/美法仑减强度预处理者HCT后早期供者髓系嵌合<50%更常见。

关键数值与推荐

  • 完全(>95%)供者髓系嵌合者血小板计数高于低水平(5%-49%)嵌合者。

临床怎么用

  • 支持WAS患者早期行HCT的推荐。
  • 无论清髓或含白消安的减强度预处理,均应追求高水平供者髓系嵌合以促进血小板重建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wiskott-Aldrich syndrome (WAS) is an X-linked disease caused by mutations in the WAS gene, leading to thrombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy. Hematopoietic cell transplantation (HCT) is the primary curative approach, with the goal of correcting the underlying immunodeficiency and thrombocytopenia. HCT outcomes have improved over time, particularly for patients with HLA-matched sibling and unrelated donors. We report the outcomes of 129 patients with WAS who underwent HCT at 29 Primary Immune Deficiency Treatment Consortium centers from 2005 through 2015. Median age at HCT was 1.2 years. Most patients (65%) received myeloablative busulfan-based conditioning. With a median follow-up of 4.5 years, the 5-year overall survival (OS) was 91%. Superior 5-year OS was observed in patients <5 vs ≥5 years of age at the time of HCT (94% vs 66%; overall P = .0008). OS was excellent regardless of donor type, even in cord blood recipients (90%). Conditioning intensity did not affect OS, but was associated with donor T-cell and myeloid engraftment after HCT. Specifically, patients who received fludarabine/melphalan-based reduced-intensity regimens were more likely to have donor myeloid chimerism <50% early after HCT. In addition, higher platelet counts were observed among recipients who achieved full (>95%) vs low-level (5%-49%) donor myeloid engraftment. In summary, HCT outcomes for WAS have improved since 2005, compared with prior reports. HCT at a younger age continues to be associated with superior outcomes supporting the recommendation for early HCT. High-level donor myeloid engraftment is important for platelet reconstitution after either myeloablative or busulfan-containing reduced intensity conditioning. (This trial was registered at www.clinicaltrials.gov as #NCT02064933.).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020. PMID: 32268350. doi:10.1182/blood.2019002939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。